Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer.

Rhodé M BijlsmaRoel WoutersHester WesselsStefan SleijferLaurens BeerepootDaan Ten Bokkel HuininkHester CruijsenJoan HeijnsMartijn P LolkemaNeeltje SteeghsTheo van VoorthuizenAnnelie VulinkEls WitteveenMargreet AusemsAnnelien BredenoordAnne M MayEmile E Voest

Published in: ESMO open (2021)

Our study showed that the vast majority of patients with cancer desires to receive all UFs of genome testing, although a substantial minority does not wish to receive non-actionable findings. Incorporation of categories in informed consent procedures supports patients in making informed decisions on UFs.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
genome wide
peritoneal dialysis
single cell
gene expression
patient reported outcomes